WealthCollab’s AnaptysBio ANAB Stock Holding History

WealthCollab’s Portfolio ANAB Stock Details ANAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-20	Closed	-$265	–	918
2024 Q4	$265	Buy	+20	New	+$484	﹤0.01%	862

Other funds holding ANAB

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCM

Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

WealthCollab's ANAB Position: Q1 2025 in Review

WealthCollab sold out of AnaptysBio (ANAB) in Q1 2025, closing a stake of 20 shares — an estimated $265 sold.

WealthCollab first reported a position in ANAB in Q4 2024 and held it in 1 quarter. The position peaked at $265 in Q4 2024. 153 funds tracked by Wall St. Rank hold ANAB as of Q1 2025.

WealthCollab reported no remaining AnaptysBio position as of Q1 2025 after selling out during the quarter.
WealthCollab sold 20 AnaptysBio shares in Q1 2025, an estimated $265.
WealthCollab first reported a position in AnaptysBio in Q4 2024 and held it in 1 quarter.
WealthCollab's AnaptysBio position peaked at $265 in Q4 2024.
153 funds tracked by Wall St. Rank held AnaptysBio as of Q1 2025.

Based on WealthCollab's 13F filing for Q1 2025, filed 14 May 2025.